Advertisement

Business

Updated on: Friday, August 13, 2021, 11:44 PM IST

Glenmark Pharma Q1 net up 21% at Rs 306 cr; 'landmark quarter', says CMD

PTI
Glenmark Life Sciences' IPO was subscribed 44.17 times last month | Photo credit: Twitter

Glenmark Life Sciences' IPO was subscribed 44.17 times last month | Photo credit: Twitter

Advertisement

Glenmark Pharmaceuticals on Friday said its consolidated profit after tax (PAT) increased by 21 per cent to Rs 306 crore for the first quarter ended June 30.

The Mumbai-based drug major had reported a PAT of Rs 254 crore in the April-June quarter of the 2020-21 fiscal.

The company's consolidated revenue rose to Rs 2,965 crore from Rs 2,345 crore in the Q1 of last fiscal.

"It was a landmark quarter for the company with positive momentum in all our key markets. Our commitment towards the fight against COVID-19 was reflected in FabiFlu becoming the number one brand in the India pharma market in April.

"We launched our first nebuliser, Arformoterol Inhalation solution from Monroe, US," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said in a statement.

The company has a strategic roadmap to grow consistently and profitably over the year, he added.

"We have a clear plan in place to reduce debt by enhancing free cash, prioritising over R&D investments and capital expenditure going forward," Saldanha noted.

(To receive our E-paper on whatsapp daily, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

Published on: Friday, August 13, 2021, 11:44 PM IST
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement